Health ❯ Vaccines

Flu Vaccine

FluMist AstraZeneca Effectiveness FDA Approval FDA Advisory Panel mRNA Technology Public Health Moderna Recommendations Effectiveness Over Time mRNA Vaccines Vaccine Hesitancy

FDA Reverses Course To Review Moderna’s mRNA Flu Shot Under Split Pathway

The reversal follows a rare refusal-to-file over the trial comparator for seniors, with a decision due August 5.

AstraZeneca Launches FluMist Home Direct-to-Consumer Nasal Vaccine in 34 States